phrykt

OptimizeRx Corp (OPRX): who owns it and who trades it

As of Nov 16, 2026, OPRX insiders reported 1 open-market sale worth $18.8K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Edward Stelmakh (Chief Finance & Strat Of), with $18.8K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling OptimizeRx

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns OPRX

113 funds and institutions reported OPRX shares worth $64.2M at the end of Q2 2026, about 60% of the company. The largest holder is Whetstone Capital Advisors, LLC with 8.0%.

Funds and institutions (13F) 60%Everyone else 40%

10 largest owners, by share of the company

Whetstone Capital Advisors, LLC8.0%
Royce & Associates LP5.8%
Vanguard Capital Management LLC3.7%
Kennedy Capital Management LLC3.4%
Rice Hall James & Associates, LLC3.4%
Blair William & Co3.2%
AQR Capital Management LLC3.1%
Dimensional Fund Advisors LP2.5%
BlackRock, Inc.2.4%
Parkman Healthcare Partners LLC1.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Whetstone Capital Advisors, LLC1.51M8.04%$8.6MNo change
Royce & Associates LP1.09M5.81%$6.2M+23%
Vanguard Capital Management LLC699,6043.73%$4M+2%
Kennedy Capital Management LLC644,1503.43%$3.7M-2%
Rice Hall James & Associates, LLC633,8423.38%$3.6M+5%
Blair William & Co607,9253.24%$3.5M-1%
AQR Capital Management LLC583,9563.11%$3.3M+172%
Dimensional Fund Advisors LP477,6872.55%$2.7M-15%
BlackRock, Inc.445,3822.37%$2.5M-62%
Parkman Healthcare Partners LLC350,3471.87%$2M-52%
Bullseye Asset Management LLC258,3111.38%$1.5M+14%
AWM Investment Company, Inc.240,4211.28%$1.4M+4%
Geode Capital Management, LLC207,3451.10%$1.2M-47%
Vanguard Portfolio Management LLC169,5380.90%$970K-49%
Renaissance Technologies LLC167,7000.89%$959K-23%
Marshall Wace, LLP162,1860.86%$928K+418%
P.a.w. Capital Corp160,0000.85%$915K+78%
Citadel Advisors LLC157,9920.84%$904K–
Morgan Stanley156,3140.83%$894K+105%
Mink Brook Asset Management LLC141,2350.75%$808K–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, OPRX insiders reported $0 of open-market purchases and $18.8K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$18.8K
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Dec 19, 2025
Filed Dec 22, 2025

Purchases and sales by month

$18.8K$18.8KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 19, 2025Edward StelmakhChief Finance & Strat OfSale1,388$13.51$18.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Edward StelmakhChief Finance & Strat Officer–$18.8KDec 19, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

OPRX short interest

Moderate short interest. 6.3% of OPRX shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went down 41%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.19M OPRX shares were sold short, 6.3% of the shares outstanding, up 10.1% from the report before. At the average daily volume of 121,784 shares, buying them all back would take about 9.8 trading days (days to cover).

Shares short, % of all shares

6.28%May 15Oct 3011.5%

Days to cover

9.8May 15Oct 3010.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.19M6.28%+10%121,7849.8
Oct 15, 20261.08M5.72%-3%160,5196.7
Sep 30, 20261.12M5.93%+11%193,5975.8
Sep 15, 20261.01M5.36%-13%108,3269.3
Aug 31, 20261.16M6.17%+1%184,4786.3
Aug 14, 20261.15M6.12%-15%305,1413.8
Jul 31, 20261.36M7.21%-7%214,2876.3
Jul 15, 20261.46M7.78%+29%346,7424.2
Jun 30, 20261.13M6.02%-39%624,5221.8
Jun 15, 20261.85M9.87%+7%292,4366.3
May 29, 20261.73M9.22%-14%431,5454.0
May 15, 20262.01M10.73%-7%634,4213.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

OptimizeRx company events

OptimizeRx filed 7 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership, auditor). The latest was on Aug 12, 2026.

  1. Aug 12, 2026LeadershipThe Board of Directors of OptimizeRx Corporation approved a finance leadership succession plan. Filing
  2. Jun 12, 2026LeadershipAt the OptimizeRx Corporation 2026 Annual Meeting of Shareholders, shareholders approved an amendment to the OptimizeRx Corporation 2021 Equity Incentive Plan to increase the number of shares of common stock available for awards under the Equity Plan by 1,000,000 shares to 5,450,000 shares . A… Filing
  3. Jun 5, 2026LeadershipAs previously disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, OptimizeRx Corporation and Theresa Greco agreed on May 11, 2026 to a separation, effective as of June 15, 2026. Filing
  4. May 12, 2026AgreementOptimizeRx Corporation, a Nevada corporation, entered into a credit agreement with the other loan parties from time to time party thereto, the lenders from time to time party thereto, and Fifth Third Bank, National Association, as Agent, L/C Issuer and Swing Line Lender. Filing
  5. Apr 9, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Filing
  6. Mar 30, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  7. Mar 5, 2026AgreementOptimizeRx Corporation entered into Amendment No. 4 to the Financing Agreement. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

OptimizeRx financials

Famous investors that hold OPRX

3 of the 50 well-known investors we track reported holding OPRX in their latest 13F filing. The largest position is Ken Griffin's, worth $1.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026166,275$1.4M0.0%+5%
Israel Englander · Millennium ManagementQ3 202659,038$493K0.0%-25%
Jim Simons · Renaissance TechnologiesQ3 202654,800$458K0.0%-67%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named OPRX in the last 120 days.

FiledHolderFormStake
Oct 21, 2026ROYCE & ASSOCIATES LP13G/A7.0%
Oct 21, 2026ROYCE & ASSOCIATES LP13G/A7.0%

Questions about OptimizeRx Corp (OPRX) stock

Who owns the most OPRX stock?

The largest reported owner of OptimizeRx Corp (OPRX) is Whetstone Capital Advisors, LLC, with 8.0% of the company. In total, 113 funds and institutions reported holding OPRX at the end of Q2 2026, together about 60% of the shares. See the largest owners.

Are OPRX insiders buying or selling?

In the last 12 months, OPRX insiders reported no open-market purchases and 1 sale worth $18.8K. The latest trade was on Dec 19, 2025. See every trade.

What is the short interest in OPRX?

As of Oct 30, 2026, 1.19M OPRX shares were sold short, 6.3% of the shares outstanding, up 10.1% from the report before. At the average daily volume of 121,784 shares, buying them all back would take about 9.8 trading days (days to cover). See the history.

Which famous investors hold OPRX?

3 of the 50 well-known investors we track reported OPRX in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $1.4M. See all holders.

Executive pay

OptimizeRx's chief executive was paid a total of $2.7M for the year ended Dec 31, 2025. In the last 12 months, OptimizeRx's executives and directors bought no stock on the open market and sold $18.8K.

Chief executive, total pay$2.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$3.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.